Companies Cryptocurrencies
Gossamer Bio Inc
Gossamer Bio Inc
Exchange: NasdaqGS
IPO Date: 08/02/2019
CEO: Dr. Sheila Gujrathi
Biotechnology Healthcare 🔗
  • GOSS
  • 11.87
  • 902042880
    market cap
  • -0.46000004
If you bought

shares of Gossamer Bio Inc (GOSS) on
You would have made
Old Price $12 Current Price $12

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 118 full-time employees. The firm has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program. GB001 is an oral antagonist of prostaglandin D2 receptor 2, or DP2, is being developed for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor is being developed for the treatment of pulmonary arterial hypertension. GB004 is being developed for Inflammatory Bowel Disease (IBD). GB1275 is a CD11b agonist.

Address: 3013 Science Park Rd San Diego CALIFORNIA 92121

Stay updated.